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Transplant renal artery stenosis (TRAS) is the most frequent vascular complication after kidney transplantation (KT) and has been
associated with potentially reversible refractory hypertension, graft dysfunction, and reduced patient survival.The aim of the study
is to describe the outcomes of a standardized Duplex Ultrasound- (DU-) based screening protocol for early diagnosis of TRAS and
for selection of patients potentially requiring endovascular intervention. We retrospectively reviewed our prospectively collected
database of KT from January 1998 to select patients diagnosed with TRAS. The follow-up protocol was based on a risk-adapted,
dynamic subdivision of eligible KT patients in different risk categories (RC) with different protocol strategies (PS). Of 598 patients
included in the study, 52 (9%) patients had hemodynamically significant TRAS and underwent percutaneous angioplasty (PTA) and
stent placement. Technical and clinical success rates were 97% and 90%, respectively. 7 cases of restenosis were recorded at follow-
up and treated with re-PTA plus stenting. Both DU imaging and clinical parameters improved after stent placement. Prospective
high-quality studies are needed to test the efficacy and safety of our protocol in larger series. Accurate trial design and standardized
reporting of patient outcomes will be key to address the current clinical needs.
1. Introduction
Kidney transplantation (KT) represents the treatment of
choice for end-stage renal disease (ESRD) [1]. Although both
outcomes and survival have been improved by standardiza-
tion of surgical techniques, perioperative management, and
immunosuppressive regimens, postoperative complications
remain frequent in surgical practice [2]
Transplant renal artery stenosis (TRAS) is considered
the most frequent vascular complication after KT with an
overall incidence of 1–23% and prevalence of 1,5–4% [1].
TRAS is generally observed 3–24 months after KT [3] and its
incidence has progressively increased due to amore extensive
use of noninvasive diagnostic procedures [4]. However, to
date, conventional angiography remains the gold standard
for diagnosis and provides the guidance for percutaneous
transluminal angioplasty (PTA) with or without endovascu-
lar stenting [1].
As TRAS has been associated with potentially reversible
refractory hypertension [5], graft dysfunction, and reduced
patient survival [6, 7], its early diagnosis and prompt man-
agement still represent key clinical needs.
Nonetheless, the wide variability of reported incidence
rates of TRASmay reflect the lack of standardized definitions
of hemodynamically significant disease [8], clinical rele-
vance [1], and technical/clinical success in current surgical
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series [4]. Of note, the lack of specific Doppler ultrasound
follow-up protocols prevents a prompt diagnosis of asymp-
tomatic TRAS in most patients, with potential delay of
treatment and associated worsening of long-term graft renal
function. Therefore, a critical unmet need is to select a
noninvasive diagnostic work-up to screen asymptomatic KT
patients to early diagnose those patients with hemodynami-
cally significant TRAS deserving further invasive diagnostic
and therapeutic procedures [4].
The aim of the study is to describe the outcomes of our
standardized screening protocol in patients undergoing KT
focusing on the role of Duplex Ultrasound (DU) imaging
for early diagnosis of TRAS and for selection of patients
potentially requiring endovascular intervention.
2. Materials and Methods
2.1. Surgical Technique. All KTs were performed with open
surgery by a dedicated transplant team composed by 5 highly
experienced surgeons according to a standard operative tech-
nique [9]. For KT, end-to-side anastomoses were performed
between the graft vessels and the external iliac vein and artery
using a Carrel patch. In two cases, an end-to-end arterial
anastomosis using the internal iliac artery and, in 13 cases,
an end-to-side arterial anastomosis between the graft renal
artery and common iliac artery were performed. Ureteral
neocystostomywas performed extravesically according to the
Lich-Gregoir or Barry techniques using a double J ureteral
stent as guidance.
2.2. Patient Population and Study Design. After Institutional
Ethical Committee approval, our prospectively collected
database of patients undergoing KT from brain-dead heart-
beating donors at Careggi University Hospital from January
1998 was retrospectively reviewed to select patients enrolled
in our standardized DU-based follow-up protocol diagnosed
with TRAS.
2.3. Duplex Ultrasound Criteria for Suspicion of TRAS. The
evaluation of the vascular axis of the transplanted kidney was
performed according to standardized imaging protocols [8].
All DU evaluations were performed by 4 radiologists with
extensive experience in KT imaging.
DU criteria for suspicion of TRAS used in our study are
depicted in Table 1. In particular, DU imaging was focused
on the research of pathological vascular flows within the
arterial axis of the transplanted kidney that were suspect for
hemodynamically significant stenosis.
No specificmorphological abnormalities of the transplant
renal artery were considered sufficient to raise the suspicion
of TRAS, independently from their location (i.e., anastomotic
and postanastomotic).
In our protocol, an increase in systolic peak velocity
(SPV) at the level of the flow abnormality at DU imaging
(site of the potential stenosis) was considered the mandatory
parameter to raise the suspicion of TRAS. Other DU parame-
ters traditionally associated with TRUS were (a) the manifes-
tation of tardus-parvus waveform and (b) reduced resistive
Table 1: Duplex Ultrasound (DU) criteria for suspicion of TRAS in
the study. SPV > 2,2m/sec was considered the landmark value for
suspicion of TRAS > 50%, while a SPV > 2,8m/sec was considered
the landmark value for suspicion of TRAS > 70%, which we
considered hemodynamically significant according to the available
evidence (Ngo). Tardus-parvus waveform and reduced RI were
considered accessory parameters that might increase the degree of
suspicion in case of symptoms or altered SPV. TRAS = transplant
renal artery stenosis; SPV = systolic peak velocity; RI = resistive
indexes.
Direct criteria
(mandatory criterion)
SPV > 2,8m/sec (suspicion of TRAS > 70%)
(at the level of presumed stenosis)
SPV > 2,2m/sec (suspicion of TRAS > 50%)
(at the level of presumed stenosis)
Indirect criteria
(accessory criteria)
Tardus-parvus waveform
(at parenchymal level)
Reduce RIs (<0,8)
(at parenchymal level)
indexes (RI) at parenchymal level. However, being affected
also by parenchymal conditions, they represent indirect signs
not specific for TRAS not sufficient nor necessary for DU
suspicion of TRAS.
2.4. Follow-Up Protocol. The DU-based follow-up protocol
for early detection of TRAS was performed in addition to the
regular follow-up visits routinely defined by the KT Protocol
at our institution in accordancewith the current international
Guidelines [10]. Estimated glomerular filtration rate (eGFR)
was calculated using the CKD-EPI 2009 formula and was
used as a surrogate for allograft function, while systolic,
diastolic, and mean arterial blood pressure (ABP) was used
to assess cardiovascular status.
According to our protocol, DU imaging was scheduled in
all eligible patients at day 3 after KT, at discharge, then at 1, 3,
6, and 12 months, and annually thereafter.
The timing of DU investigations was defined according to
the standard surveillance protocols used in vascular surgery
after carotid stenosis treatment [11].
The follow-up protocol was based on a risk-adapted,
dynamic subdivision of eligible KT patients in different
risk categories (RC) according to (a) presence of symp-
toms, namely, refractory hypertension, that is, failure to
achieve optimal blood pressure control to levels less than
140/90mmHg despite the concomitant use of 3 or more
different classes of antihypertensive agents and/or worsening
of renal function (rising of serum creatinine >20% of basal
value, after excluding all other potential sources of graft
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Table 2: Overview of the protocol strategies (PS) for early detection of TRAS according to the patient’s individual risk category (RC). Patients
were defined as symptomatic in case of refractory hypertension (defined as failure to achieve optimal blood pressure control to levels less
than 140/90mmHg despite the concomitant use of 3 or more different classes of antihypertensive agents) and/or worsening of renal function
(defined as rising of serum creatinine >20% of basal value, after excluding all other potential sources of graft impairment). RC1 patients
continued PS1, RC2 and RC4 patients followed a stricter follow-up (PS2) to reclassify the patient in a different RC; finally, RC3 and RC 5
patients were candidate for immediate angiography +/− PTA and stenting. TRAS = transplant renal artery stenosis; SPV = systolic peak
velocity.
Symptoms
(refractory hypertension and/or
worsening of renal function)
VPS
(m/sec)
Risk
category
(RC)
Protocol strategy
(PS)
No
<2,2 1 1. Regular ECD follow-up at 3
∘ POD, discharge, 1, 3, 6, 12 months then
annually
2,2–2,8 2 2. ECD imaging monthly until reclassification in a different RCwithin 1-year period
>2,8 3 3. Indication for angiography +/− PTA +/− stenting
Yes <2,2 4
2. ECD imaging monthly until reclassification in a different RC
within 1-year period
>2,2 5 3. Indication for angiography +/− PTA +/− stenting
impairment) [12]; (b) DU criteria for suspicion of TRAS
(Table 1).
Asymptomatic patients were assigned to RC 1, RC 2, or
RC 3 if DU imaging was negative for suspicion of TRAS (VPS
< 2,2m/sec at the level of presumed arterial stenosis), suspi-
cious for TRAS (VPS > 2,2m/sec but lower than 2,8m/sec),
or suspicious for hemodynamically significant TRAS (VPS
> 2,8m/sec), respectively. On the contrary, symptomatic
patients were classified into RC 4 and RC 5 based on DU
findings as follows: RC 4, if VPS < 2,2m/sec; RC 5, if VPS
> 2,2m/sec, in both cases after differential diagnosis excluded
other potential causes of refractory hypertension or worsen-
ing renal function.
Our approach ultimately identified three different pro-
tocol strategies (PS): PS1, continuation of regular follow-
up imaging (at the predefined time intervals); PS2, inten-
sification of the follow-up schedule (DU imaging monthly
until reclassification in a different RC within 1-year period);
PS3, indication for conventional angiography and possible
concomitant PTA treatment, after a confirmatory DU exam-
ination.
According to the above discussed principles, each KT
patient was assigned a RC and a specific PS as follows
(Table 2):
(i) RC 1 patients continued PS1.
(ii) RC 2 and RC 4 patients were followed more strictly
(PS2) in order to be dynamically reclassified within
an established period (1 year) in a different RC.
(iii) RC 3 andRC5 patientswere candidates for immediate
angiography +/− PTA and stenting.
2.5. Angiography and Endovascular Intervention. In patients
with high suspicion of TRAS (RC 3 and RC 5), conventional
or digital subtraction angiography was performed according
to the standard technical principles [13].
According to the results of angiographic imaging, patients
were reclassified into the following groups:
(1) Patients with no angiographic evidence of TRAS
(2) Patients with angiographic evidence of TRAS < 50%
(3) Patients with angiographic evidence of TRAS > 50%
and <70%
(4) Patients with angiographic evidence of TRAS > 70%
(hemodynamically significant TRAS).
Techniques of angiography, PTA, and stent placement were
previously described [14] and shown in Figure 1. Patients with
angiographic evidence of TRAS > 70% were always treated
with PTA and stenting if hemodynamic pressure measure-
ments showed a systolic pressure gradient of 20mmHg or
more. On the contrary, patients with TRAS of 50–70% were
treated with PTA only if the systolic pressure gradient did not
exceed the threshold of 20mmHg.
Technical success was defined as an endovascular inter-
vention resulting in complete restoration of renal allo-
graft perfusion without any significant residual stenosis as
determined by a negligible systolic pressure gradient or
fluoroscopic visualization in cases where pressure measure-
ments were unavailable. In particular, technical success was
achieved in case of residual stenosis less than 30% after
endovascular intervention, with residual peak systolic pres-
sure gradient less than 10mmHg across the lesion. After
endovascular intervention, all patients continued the follow-
up according to the PS1 schedule. For asymptomatic patients
with TRAS treated with PTA and stenting, definition of clin-
ical success relied on the absence of restenosis of transplant
renal artery during the long-term follow-up requiring rein-
tervention (either repeated PTA +/− stent or open surgery).
For symptomatic patients with TRAS treated with PTA and
stenting, beyond the previously described criterion, clinical
success was also defined as reduction of ABP values and of the
number of chronic antihypertensive medications, as well as
improvement/stability in renal function.
Both clinical (systolic and diastolic blood pressure,
eGFR) and DU parameters (PSV, RI) of patients undergoing
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Figure 1: Percutaneous angioplasty and stent placement for anastomotic TRAS. In all patients, a nonselective aortoiliac arteriogram was
performed to exclude any preanastomotic (proximal-TRAS) inflow stenosis in the recipient arteries. The stenotic lesion was dilated with
a 4.8-French angioplasty balloon catheter passed through a valved 8-French introducer sheath via a femoral approach. Where indicated, the
intravascular stent (Palmaz endoprosthesis) was implanted over a stiff 0.5mm guide wire passed carefully through the stenosis, measuring
the pressure gradients. In case of hemodynamically significant stenosis, 3000–5000U of heparin was administered intravenously and balloon
dilation is performed. Balloon-size selection was based on direct measurement of the diameter of a normal nondiseased renal artery segment,
as previously described (hederman). Then the bare-metal stent was inserted and left in place in the transplant renal artery after the removal
of the guide wire and balloon catheter. A postangioplasty arteriogram was always obtained.
PTA + stenting were recorded at 1-month follow-up after the
endovascular procedure.
2.6. Allograft Survival. Allograft loss was defined by the need
for permanent dialysis as documented by the renal transplant
team notes, which occurred at regular intervals following
KT. Outcomes in allograft survival were censored for patient
survival.
2.7. Statistical Analysis. Statistical analyses and reporting of
results were conducted according to recently published [15].
First, descriptive statistics were obtained for all variables.
Since sample data failed to meet most assumptions for
parametric testing, all statistical analyses were performed
with nonparametric tests. Continuous variables are presented
as medians and interquartile (IQR) range, while categorical
variables are presented with frequencies and proportions.
The Wilcoxon signed-rank test was used to compare mean
SPV, RI, Systolic ABP, diastolic ABP, and eGFR values among
the TRAS-patients before and after stent placement. The
Kruskal-Wallis test was used to compare themeanΔSPV,ΔRI,
ΔSBP, ΔDBP, and ΔeGFR values among the TRAS-patients at
different time periods from renal transplantation (<3months,
3–12 months, and >12 months). All tests were two-sided with
a significance level set at 𝑝 < 0.05. All statistical tests were
performedusing SPSS v.18.0 (IBMCorp., Armonk,NY,USA).
3. Results and Discussion
3.1. Results. Overall, 946 patients underwent KT at our
institution from July 1991. Of these, patients undergoing KT
before January 1998 (140/946, 15%) were not eligible for the
study as there was no standardized follow-up protocol for
early detection of TRAS.
Of the 806 patients undergoing KT from January 1998,
patients experiencing medical or surgical complications in
the postoperative period, patients with unavailable clinical
data, and patients lost at follow-up were excluded from the
study.
Thus, 620/806 (77%)were enrolledwithin a standardized,
DU-based follow-up protocol for early detection of TRAS.
During follow-up, 18/620 (3%) patients for whom serial
DU imaging could identify the presence of morphological
transplant renal artery kinking (TRAK) were also excluded
from the study protocol.
Finally, 598 patients had complete data available and
constituted our study population.
The flow-chart detailing the study design is shown in
Table 3.
Of 598 KT patients included in the study, 59 (10%)
patients with clinical or DU suspicion of TRAS under-
went diagnostic angiography and 56/59 (95%) patients were
diagnosed with TRAS at angiographic evaluation. Thus, the
incidence of TRAS in our series was 9%.
Of patients diagnosed with TRAS, 35/56 (62%) weremale
and 21/56 (38%) female. Median age at KT was 55 years (IQR
43–69). Median time fromKT to TRAS diagnosis was 71 days
(IQR 22–130). Most of the TRAS were located at the level
of the anastomosis (30/56, 54%), while the other cases were
preanastomotic (6/56, 10%) or postanastomotic (20/56, 36%).
In 3/59 (5%), no evidence of TRAS was shown, of which
there was 1 case of TRAK. These patients continued the
regular noninvasive follow-up protocol (PS1).
Among the 56 patients with angiographic diagnosis of
TRAS, 1 case showed a TRAS < 50% and no further treatment
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Table 3: Flow-chart detailing the study design. TRAS = transplant renal artery stenosis.
Patients undergoing kidney transplantation from July 1991 at Careggi University Hospital
(𝑛 = 946)
Patients eligible for the standardized ECD- based
follow-up protocol for early detection of TRAS (started on
January 1998)
(𝑛 = 806, 85%)
Patients undergoing KT from 1991 to 1998 excluded due
to lack of standardized follow- up protocols for diagnosis
of TRAS
(𝑛 = 140, 15%)
Patients enrolled in the standardized follow-up protocol
with complete clinical data available
(𝑛 = 620, 77%)
Patient excluded due to the following
(i) Any medical or surgical complications in the
postoperative period
(ii) Unavailable clinical data
(iii) Lack of follow-up data
(𝑛 = 186, 23%)
Patients enrolled in the study undergoing regular
follow-up at our Institution
(Study population)
(𝑛 = 598, 97%)
Patients with ECD diagnosis of transplant renal artery
kinking (TRAK) excluded from the study
(𝑛 = 18, 3%)
Patients with clinical or ECD suspicion of TRAS
undergoing diagnostic angiography
(𝑛 = 59, 10%)
Patients continuing the Protocol Strategies according to
the specific risk categories
(Table 2)
(𝑛 = 539, 90%)
Patients diagnosed with TRAS
(𝑛 = 56, 95%)
Patients with no evidence of TRAS, of which 1 TRAK,
continuing the regular follow-up protocol
(𝑛 = 3, 5%)
Patients with TRAS < 50% continuing regular follow-up
protocol
(𝑛 = 1; 2%)
Patients with TRAS of 50–70% with a peak systolic
pressure gradient across the stenosis of <20mmHg
undergoing PTA only
(𝑛 = 3; 5%)
Patients with TRAS > 70% with a peak systolic pressure
gradient across the stenosis of >20 mmHg undergoing
PTA + Stenting
(𝑛 = 52; 93%)
Patients undergoing diagnostic angiography for suspicion
of TRAS during follow-up
(𝑛 = 8, 14%)
Patients with re-TRAS treated with re-PTA + stenting
(𝑛 = 7)
Patients with no evidence of TRAS continuing the regular
follow-up protocol
(𝑛 = 1)
was performed (PS1). In 3 (5%) patients, a TRAS of 50–70%
with a peak systolic pressure gradient across the stenosis of
<20mmHg was shown; in these cases, PTA was performed
without stent placement.
In 52/56 (93%) patients hemodynamically significant
TRAS with a peak systolic pressure gradient > 20mmHg was
shown and underwent PTA plus bare-metal stent placement.
No major complications were recorded after endovascular
intervention. There were two minor hematomas which were
managed conservatively.
Overall technical success rate was 97%, while clinical
success rate was 90%.
During follow-up, 8/56 (14%) patients fulfilled the cri-
teria for a new angiographic evaluation (i.e., new onset of
symptoms or worsening of renal function with DU imaging
suspicious for TRAS).
Overall, 7 cases of restenosis were recorded at a median
time from first diagnosis of 16 months (IQR 4–20) and
were treated with a bare-metal stent (6 restenting procedure
and 1 de novo procedure in a patient previously treated
with PTA). In one case, digital angiography did not show
hemodynamically significant TRAS.
Overall, of the 52 patients treated with PTA + stent place-
ment, 18/52 (34%) patients died after amedian (IQR) survival
of 87 (49–130) months and 9/52 (18%) were lost to follow-up
(Supplementary Figure 1). Causes of death included neoplas-
tic diseases, cardiovascular/respiratory events or infections
(Supplementary Table 1). Median (IQR) graft survival was
87 (49–130) and 58 (56–119) among patients that died with
(𝑛 = 15) and without (𝑛 = 3) a functioning graft, respectively.
On the contrary, among the 25 alive patients, after a median
(IQR) follow-up of 154 (79–176) months, 18/25 (72%) have
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Table 4: Comparison of SPV, RI, SBP, DBP, and eGFR values among the TRAS-patients before and after stenting placement. TRAS = transplant
renal artery stenosis; SPV = systolic peak velocity; RI = resistive indexes.
Prestenting (𝑛 = 52) Poststenting (𝑛 = 52) 𝑝 value
Systolic peak velocity (SPV) at the
level of TRAS (m/sec)
(median, IQR)
3,0 (2,6–3,6) 1,4 (1,2–1,7) <0,001
Resistive index (RI) at
parenchymal level (n)
(median, IQR)
0,68 (0,62–0,73) 0,72 (0,69–0,77) 0,01
Systolic blood pressure (mmHg)
(median, IQR) 145 (140–160) 140 (120–150) 0,1
Diastolic blood pressure (mmHg)
(median, IQR) 85 (80–90) 80 (75–85) 0,06
eGFR (ml/min/m2)
(median, IQR) 49 (35–56) 53 (41–63) 0,11
Table 5: Comparison of ΔSPV, ΔRI, ΔSBP, ΔDBP, and ΔeGFR values among the TRAS-patients at different time periods from renal
transplantation. TRAS = transplant renal artery stenosis; SPV = systolic peak velocity; RI = resistive indexes.
Time to TRAS treatment
𝑝 value<3 months
(𝑛 = 16)
3–12 months
(𝑛 = 11)
>12 months
(𝑛 = 25)
Δ systolic peak velocity (SPV) at the
level of TRAS (poststent SPV − prestent
SPV)
(ml/min) (median, IQR)
−1,5 (−1,7; −0,7) −1,6 (−1,9 −1,1) −1,5 (−1,8; −1,2) 0,9
Δ resistive index (RI) at parenchymal
level (poststent RI − prestent RI)
(𝑛) (median, IQR)
0,0 (−0,01; 0,09) 0,06 (0,00–0,12) 0,3 (0,01–0,08) 0,5
Δmean systolic blood pressure (SBP)
(poststent SBP − prestent SBP)
(mmHg) (median, IQR)
−10,0 (−20,0; 0,0) −10,0 (−40,0; 0,0) −12,0 (−34; 2,0) 0,4
Δmean diastolic blood pressure (DBP)
(poststent DBP − prestent DBP)
(mmHg) (median, IQR)
0,0 (−10; 5,0) −10,0 (−20,0; 5,0) 5,0 (−14; 8,0) 0,3
Δmean eGFR (poststent − prestent)
(ml/min/m2)
(median, IQR)
8,5 (−1,0; 25) 5,0 (−8,0; 16,0) 6,5 (−2; 18) 0,4
currently a functioning graft while 7/25 (28%) require redial-
ysis.Median (IQR) graft survival among these patient cohorts
was 128 (73–155) and 113 (85–130) months, respectively
(Supplementary Figure 1).
Table 4 shows the comparison of mean SPV, RI, Systolic
and diastolic ABP, and eGFR values among the 52 TRAS-
patients before and after stenting placement, while Table 5
describes the comparison of the results of stent placement
in patients treated at different time periods from KT (first 3
months, 3–9 months, and 1 year of after).
Overall, both DU imaging and clinical parameters
improved after stent placement. In particular, median value
of mean SPV at the level of TRAS was significantly lower
after stent placement (1,4 versus 3,0m/sec, 𝑝 < 0,001),
as well as diastolic blood pressure (80 versus 85mmHg,
𝑝 = 0,06). Median values of mean RI were significantly
higher after the procedure (0,72 versus 0,68, 𝑝 = 0,01); both
systolic blood pressure and serum creatinine values were
also improved after endovascular intervention, even if not
reaching statistical significance (Table 4).
There was no statically significant difference between the
single Δ (post − pre) values of PSV, RI, systolic or diastolic
ABP, and eGFR amongpatientswithTRAS treated at different
time periods from KT (Table 5).
3.2. Discussion. Our study aimed to provide evidence on the
outcomes of a standardized DU-based follow-up protocol of
patients undergoing KT for screening and early diagnosis of
TRAS through a retrospective analysis of a large series. We
found an overall incidence of TRAS of 9% (56/598 patients,
Table 3). The technical and clinical success rates of PTA and
stenting for patients with hemodynamically significant TRAS
were 97% and 90%, respectively.
Several studies have highlighted the negative prognostic
role of TRAS in terms of allograft dysfunction, refractory
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hypertension, and inferior graft survival in absence of prompt
intervention [6, 16, 17]. Unfortunately, the actual incidence of
TRAS is still unclear in the KT literature with broad ranges
(1–23%, [17]) due to the lack of standard definitions of clinical
or DU diagnostic criteria for the disease [1, 4]. At the same
time, TRAS might have a multifactorial etiology that may
generate confusion regarding its best management [1].
In this scenario, early diagnosis of TRAS is key to improve
the care of KT patients by selecting those deserving invasive
therapeutic procedures. However, to date, diagnosis of TRAS
still relies on angiographic imaging, exposing many patients
to invasive, costly, and potentially harmful diagnostic tech-
niques. In this regard, the number of patients with suspicion
of TRAS that needs to undergo conventional angiography to
detect a hemodynamically significant disease is still unclear
[10], raising concerns of the true utility of angiography as the
gold standard diagnostic tool. Moreover, computed tomogra-
phy angiography and magnetic resonance angiogram are still
no ideal diagnostic techniques, as they are costly, not easily
available, potentially associated with graft toxicity and unable
to provide guidance for concomitant treatment. Therefore,
the most recent Guidelines of the European Association of
Urology (EAU) on KT stress the concept of DU imaging
as a noninvasive, economical screening technique to select
patients with suspicion of TRAS requiring further diagnostic
and therapeutic interventions. Yet, no standardized follow-
up protocols based on DU are proposed [10]. In this context,
our study addresses the critical unmet need of defining
a standardized, noninvasive diagnostic work-up to screen
asymptomaticKT patients for TRAS to select those deserving
further invasive diagnostic and therapeutic procedures. Our
standardized follow-up protocol was designed to adjust the
type and intensity of follow-up investigations according to
the individual patient’s risk of hemodynamically signifi-
cant TRAS based on DU criteria (Table 1). The objective
of such protocol was indeed to early detect all cases of
hemodynamically significant TRAS that would eventually
require conventional angiography, with or without PTA and
stenting. To achieve the goal, in the context of extreme
variability of DU diagnostic criteria of TRAS reported in the
current series [4], we defined a simple and reproducible DU
predictor of suspected TRAS, namely, SPV at the level of the
presumed stenosis at DU imaging. Being directly influenced
by the degree of flow abnormalities rather than indirect
signs of parenchymal damage, SPV potentially overcomes the
traditional DU criteria associated with TRAS (tardus-parvus
waveform and reduced RIs) that we consequently considered
only accessory criteria for diagnosis of suspected TRAS.
The rational for our standardized follow-up protocol
based on regular DU investigations is to arouse suspicion of
TRAS even in nonsymptomatic cases. To improve further the
diagnostic performance of the DU technique, we defined dif-
ferent categories of risk (RC) at the individual patient level by
merging clinical andDUparameters (Table 1) to select proper
risk-adjusted protocol strategies. As such, (1) asymptomatic
patients required higher SPV values than those of symp-
tomatic patients to be eligible for conventional angiography;
(2) in each category (asymptomatic versus symptomatic),
SPV values acted as drivers to select the most suitable PS
(i.e., in asymptomatic patients, PS 1 if SPV < 2,2m/sec and
PS 3 if SPV > 2,8m/sec). With such classification system
patients could also be dynamically reclassified into specific
RCs in case of borderline SPV values in both symptomatic
and asymptomatic patients by following a more strict follow-
up schedule.
Overall, our protocol defined two distinct operative
follow-up strategies, of which one is conservative (PS1, that
is, regular follow-up at predefined time intervals, Table 2)
and one is interventional (PS3, namely, the indication for
further invasive procedures). In addition, to avoid useless
angiographic procedures in those patients with unclear RC,
our protocol considered a specific protocol strategy (PS2)
that aimed to reclassify patients into PS1 or PS3 based on the
results of serial DU investigations.
The theoretical principles of the protocol were confirmed
by our results.
In our series, 52 patients were diagnosed with TRAS
at angiographic imaging and underwent PTA and stent
placement. Overall, the values of systolic and diastolic ABP, as
well as eGFR, were improved after stent placement, although
they did not reach statistical significance (Table 4). However,
the absolute values of systolic ABP before treatment were
lower than previously reported [18, 19], potentially reflecting
the ability of our protocol to raise suspicion of TRAS in
more asymptomatic patients with lower values of ABP and,
consequently, to achieve earlier diagnosis and treatment of
the disease. On the contrary, SPV values were significantly
higher before stent placement (3,0m/sec versus 1,4m/sec).
This finding underlines the ability of SPV to detect early
abnormal flow variations at the level of stenosis in patients
undergoing DU follow-up imaging and to act as surrogate of
the treatment efficacy.
Regarding the functional outcomes after endovascular
intervention, our study failed to show a statistically significant
improvement in graft renal function after the procedure,
as described by previous series [17, 20, 21]. This finding
might have different explanations. First, early diagnosis of
TRAS achieved by our protocol, especially in asymptomatic
patients, may have prevented patients to develop a relevant
functional graft impairment before the procedure. However,
the heterogeneity of the cohort might have dimmed a true
functional benefit of the endovascular intervention. In par-
ticular, the lack of stratification of patients undergoing PTA +
stenting in the specific RC 3 and RC 5 (namely, asymptomatic
patients with VPS > 2,8m/sec and symptomatic with VPS >
2,2m/sec, resp., Table 2) did not allow us to compare pre-
and postfunctional outcomes of endovascular intervention
separately for the two risk groups and then to detect a
potential overtreatment of selected patients with TRAS.
Finally, the potential delay of diagnosis associated with
our protocol may have hindered the possibility of renal
function improvement of TRAS treatment. Of note, mean
eGFR values at the time of treatment showed a relative
stability of graft renal function, reducing the likelihood of
a negative effect of time to TRAS diagnosis on functional
outcomes.
We also tested the hypothesis that the time from KT to
TRAS diagnosis might influence the outcomes of endovascu-
lar procedure (Table 5).The absence of statistically significant
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differences between the Δ values of both ABP, SPV, and
eGFR among patients diagnosed with TRAS <3 months, 3–12
months, and >12 months after KT might reflect a relative
independence of treatment’s results from the time to TRAS
diagnosis. Thus, our follow-up protocol does not seem to
delay the time for TRAS diagnosis and treatment nor to
worsen the final functional results of endovascular treatment.
Moreover, as confirmed by several reports [1, 10], most
TRAS occurred after 12 months from KT, being potentially
relatedmore to the individual biological characteristics of the
recipient rather than technical factors of KT.
Major strengths of our study are
(i) the use of a standardized follow-up protocol for
screening and early diagnosis of TRAS in a large
surgical cohort based on a noninvasive, low-cost
diagnostic modality (DU) defining specific patient
RCs and risk-adapted dynamic PSs;
(ii) the use of SPV as a reliable, reproducible and efficient
DU parameter to screen, monitor and select patients
with suspicion of TRAS for different protocol strate-
gies;
(iii) the application of a well-defined follow-up protocol
in both symptomatic and asymptomatic patients to
improve the rate of early TRAS diagnosis;
(iv) the high rates of both technical and clinical success of
endovascular intervention in patients with diagnosis
of hemodynamically significant TRAS selected by the
protocol.
Besides its strengths, our study is not devoid of limitations.
First, this is a retrospective study of a large patient cohort
covering a rather long study period. Therefore, the study
might be prone to selection, detection, and attrition biases.
In this regard, we were not able to subcategorize patients with
angiographic diagnosis of TRAS undergoing stent placement
within the RC 3 and RC 5 categories. As such, we could
not perform comparative statistical analyses between RC 3
and RC 5 patient categories to detect differences among
these groups regarding the functional benefit of endovascular
intervention. This lack of specific information on RC patient
category might have represented a relevant limitation of the
study, especially for the interpretation of the functional out-
comes. At the same time, this represents a significant starting
point for future studies based on our follow-up protocol. It is
also important to consider that, to date, there is no evidence
on the potential clinical benefit (or disadvantage) of early
versus delayed treatment of TRAS in asymptomatic patients.
Therefore, we designed our DU-based protocol with the aim
of diagnosing early significant TRAS after KT and treat it, if
confirmed by angiographic imaging, as soon as possible to
minimize the future potential detrimental consequences of
TRAS.
Second, our findings might not be completely generaliz-
able outside tertiary referral centres as bothDU investigations
and KTs were performed by highly experienced teams.
Third, due to its inherent characteristics, our protocol
cannot provide reliable estimates of the false-negative rate of
patients with TRAS (i.e., % of asymptomatic patients with
DU parameters negative for suspicion of TRUS that actually
had TRAS at angiographic imaging). However, this patient
category is rare in current clinical practice and difficult to
detect with conventional diagnostic criteria. Both the DU
criteria for suspicion of TRAS and the specific RCs and PSs
used in our protocol were adapted from available definitions
in the literature and defined according to our personal
experience. However, as shown in a recent systematic review
of the literature, there is wide heterogeneity regarding the
definitions of TRAS diagnostic criteria, the triggers for
interventions, the reporting of treatment outcomes, and types
of follow-up schedules [4, 21, 22]. As such, we designed a
follow-up protocol that could capture the different risk of
TRAS in the single KT patient and adjust the intensity and
invasiveness of treatment accordingly. Finally, our data were
insufficient to provide evidence on the potential need of
a more intensive DU-based follow-up schedule in specific
patient categories (i.e., diabetic, atherosclerotic aortoiliac
disease, and recipients of marginal donors).
Despite these limitations, our findings afford opportuni-
ties for significant further research. Prospective high-quality
studies are needed to (a) test the efficacy and safety of
our protocol in larger series; (b) evaluate the diagnostic
accuracy of such protocol compared to the current gold
standard approach based on conventional angiography for
diagnosis of TRAS; and (c) evaluate the potential clinical
advantages of personalized DU-based follow-up schedules
for early diagnosis of TRAS in patients at higher risk of TRAS
and TRAS-related complications. To do this, accurate trials
design and standardized reporting of patient outcomes will
be key to address the current clinical needs [23].
4. Conclusions
TRAS represents the main vascular complication after KT.
Early diagnosis and prompt management are key for patient
outcomes.
We have shown the feasibility, efficacy, and safety of
a standardized, risk-adjusted, DU-based follow-up proto-
col for screening and early diagnosis of TRAS in a large
cohort of patients undergoing KT at our institution. SPV
was used as the main DU parameter to raise suspicion
of TRAS. Combining patient symptoms and DU findings
into specific RCs allowed addressing each patient toward an
appropriate PS in order to avoid unnecessary angiographic
investigations and to select patients deserving endovascular
interventions.
Technical and clinical success rates in patients with
hemodynamically significant TRAS treated with endovascu-
lar intervention were noteworthy.
Future high-quality studies are needed to prove the
efficacy of our protocol in larger series and to compare it with
the current gold standard diagnostic modalities.
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